Merus NV
NASDAQ:MRUS

Watchlist Manager
Merus NV Logo
Merus NV
NASDAQ:MRUS
Watchlist
Price: 90 USD -7.14% Market Closed
Market Cap: 6.8B USD
Section:
 

Relative Value

The Relative Value of one MRUS stock under the Base Case scenario is 53.87 USD. Compared to the current market price of 90 USD, Merus NV is Overvalued by 40%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MRUS Relative Value
Base Case
53.87 USD
Overvaluation 40%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

120.8
P/S
P/S
Price to Sales
120.8
vs History
4
vs Industry
15
Median 3Y
70.7
Median 5Y
28.1
Industry
8.2
Forward
121.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-13
Median 5Y
-12.5
Industry
24.2
Forward
-15.5
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-15.6
Median 5Y
-15.6
Industry
23
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-15.5
Median 5Y
-15.5
Industry
25.5
More Details
8.8
P/B
P/B
Price to Book Value
8.8
vs History
6
vs Industry
18
Median 3Y
4.9
Median 5Y
4.6
Industry
3.3
More Details
109.6
EV/S
EV/S
Enterprise Value to Sales
109.6
vs History
4
vs Industry
13
Median 3Y
60.1
Median 5Y
21
Industry
8.6
Forward
110
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-10.1
Median 5Y
-7.8
Industry
6.1
Forward
-16.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-10
Median 5Y
-7.7
Industry
6.6
Forward
-15.4
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-12.7
Median 5Y
-11.3
Industry
8.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-12.6
Median 5Y
-11.2
Industry
6.8
More Details
23.9
EV/IC
EV/IC
Enterprise Value to IC
23.9
vs History
19
vs Industry
18
Median 3Y
12.8
Median 5Y
13.5
Industry
5.7
More Details

Multiples Across Competitors

MRUS Competitors Multiples
Merus NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NL
Merus NV
NASDAQ:MRUS
6.8B USD 120.8 -18 -16.8 -16.7
IL
Can Fite Biopharma Ltd
TASE:CANF
168.5T ILS 61 215 173.5 -4 203 864.2 -4 125 277.8 -4 116 095
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 170 980.7 -162 409.6 -197 217.1 -194 966.6
US
Abbvie Inc
NYSE:ABBV
382.8B USD 6.4 163 15.9 22.5
US
Amgen Inc
NASDAQ:AMGN
175.6B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
153.4B USD 5.3 18.9 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.7B USD 9.6 30.7 22.5 23.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 061.7 -526.1 -572.9 -557.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD 5.5 17.2 16.4 18.6
AU
CSL Ltd
ASX:CSL
84.9B AUD 3.7 18.9 12.8 15.9
NL
argenx SE
XBRU:ARGX
42.8B EUR 13.8 32.4 55.6 57.2
P/S Multiple
Revenue Growth P/S to Growth
NL
Merus NV
NASDAQ:MRUS
Average P/S: 8 671 671.4
120.8
71%
1.7
IL
C
Can Fite Biopharma Ltd
TASE:CANF
61 215 173.5
140%
437 251.2
FR
Pharnext SCA
OTC:PNEXF
34 170 980.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
10%
1
US
E
Epizyme Inc
F:EPE
2 061.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
NL
argenx SE
XBRU:ARGX
13.8
49%
0.3
P/E Multiple
Earnings Growth PEG
NL
Merus NV
NASDAQ:MRUS
Average P/E: 43.7
Negative Multiple: -18 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 203 864.2 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 409.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
163
89%
1.8
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.9
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.7
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -526.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
10%
1.7
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
32.4
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NL
Merus NV
NASDAQ:MRUS
Average EV/EBITDA: 22
Negative Multiple: -16.8 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 125 277.8 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 217.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.9
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
55.6
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NL
Merus NV
NASDAQ:MRUS
Average EV/EBIT: 24.1
Negative Multiple: -16.7 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 116 095 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 966.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.6
13%
1.4
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
57.2
N/A N/A

See Also

Summary
MRUS intrinsic value, competitors valuation, and company profile.
DCF Valuation
MRUS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MRUS stock valuation using valuation multiples.
Wall Street Estimates
MRUS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MRUS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.